Unicycive Therapeutics, Inc.(UNCY)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Unicycive Therapeutics, Inc. (UNCY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. UNCY is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Unicycive Therapeutics, Inc. reports net income of $-1.7M, free cash flow of $-7.6M. Top institutional holders of UNCY by reported 13-F value include BlackRock, Nantahala Capital Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. UNCY trades on the Nasdaq exchange and files with the SEC under CIK 1766140. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UNCY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Unicycive Therapeutics, Inc. directly from SEC EDGAR.

Net Income

$-1.7M

Free Cash Flow

$-7.6M

UNCY key financials by period

Unicycive Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202310-K$675.0K$-30.5M
FY 202210-K$951.0K$-18.1M

Institutions holding UNCY

Institutional investors reporting a position in Unicycive Therapeutics, Inc. on SEC Form 13F.
InstitutionSharesValueReported
BlackRock1,413,381$6.6M2026-06-30
Nantahala Capital Management1,401,447$6.6M2026-06-30
VANGUARD CAPITAL MANAGEMENT1,071,481$5.0M2026-06-30
Octagon Capital Advisors1,000,000$4.7M2026-06-30
DIADEMA PARTNERS792,600$3.7M2026-06-30
GEODE CAPITAL MANAGEMENT564,019$2.6M2026-06-30
Vivo Capital550,000$2.6M2026-06-30
MARSHALL WACE, LLP547,862$2.6M2026-06-30
Logos Global Management473,563$2.2M2026-06-30
STATE STREET450,162$2.1M2026-06-30
UNCY

Unicycive Therapeutics, Inc.

UNCY
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-1.72M

EPS (Diluted)

Q2 2026
EDGAR

$-0.06

Free Cash Flow

Q2 2026
EDGAR

$-7.61M

Top Institutional Holders

as of Q2 2026
$66.41M total

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…